DOP2007000073A - Compuestos para tratar la hipertensión pulmonar - Google Patents

Compuestos para tratar la hipertensión pulmonar

Info

Publication number
DOP2007000073A
DOP2007000073A DO2007000073A DO2007000073A DOP2007000073A DO P2007000073 A DOP2007000073 A DO P2007000073A DO 2007000073 A DO2007000073 A DO 2007000073A DO 2007000073 A DO2007000073 A DO 2007000073A DO P2007000073 A DOP2007000073 A DO P2007000073A
Authority
DO
Dominican Republic
Prior art keywords
pulmonary hypertension
compounds
treat pulmonary
treating
pyridazines
Prior art date
Application number
DO2007000073A
Other languages
English (en)
Inventor
Peter Sandner
Martina Klein
Bernd Riedl
Reiner Frey
Olaf Christensen
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of DOP2007000073A publication Critical patent/DOP2007000073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas y combinaciones para tratar, prevenir o atender la hipertensión pulmonar que comprenden productos farmacéuticos heterocíclicos de moléculas pequeñas y, más en particular, piridinas y piridazinas sustituidas combinadas opcionalmente con al menos un agente terapéutico adicional.
DO2007000073A 2006-04-15 2007-04-13 Compuestos para tratar la hipertensión pulmonar DOP2007000073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007929 2006-04-15

Publications (1)

Publication Number Publication Date
DOP2007000073A true DOP2007000073A (es) 2007-11-15

Family

ID=38190754

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2007000073A DOP2007000073A (es) 2006-04-15 2007-04-13 Compuestos para tratar la hipertensión pulmonar

Country Status (10)

Country Link
US (1) US8304406B2 (es)
EP (1) EP2010173A1 (es)
JP (1) JP2009533479A (es)
AR (1) AR060431A1 (es)
CA (1) CA2648957A1 (es)
DO (1) DOP2007000073A (es)
PE (1) PE20080534A1 (es)
TW (1) TW200808317A (es)
UY (1) UY30281A1 (es)
WO (1) WO2007118602A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072881A1 (en) 2012-11-08 2014-05-15 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN105294686B (zh) * 2015-11-30 2017-03-22 郑州大明药物科技有限公司 一种利奥西呱的制备方法
KR102507847B1 (ko) 2016-10-28 2023-03-08 서울대학교병원 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
US20240009190A1 (en) * 2020-01-07 2024-01-11 Shanghai Huayu Biotechnology Co., Ltd. Combination cancer therapy using chk inhibitor
US20240294537A1 (en) 2021-07-07 2024-09-05 Teva Pharmaceuticals International Gmbh SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
DE10310908A1 (de) 2003-03-13 2004-09-23 Bayer Healthcare Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von pulmonaler Hypertonie
WO2005094872A1 (en) * 2004-03-31 2005-10-13 Eyegene Inc. Polypeptide inducing the secretion of angiopoietin
JP2008503446A (ja) * 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
EP1937632A1 (en) * 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds

Also Published As

Publication number Publication date
AR060431A1 (es) 2008-06-18
US8304406B2 (en) 2012-11-06
CA2648957A1 (en) 2007-10-25
TW200808317A (en) 2008-02-16
PE20080534A1 (es) 2008-07-13
JP2009533479A (ja) 2009-09-17
EP2010173A1 (en) 2009-01-07
WO2007118602A1 (en) 2007-10-25
US20100113452A1 (en) 2010-05-06
UY30281A1 (es) 2007-11-30

Similar Documents

Publication Publication Date Title
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
IL195030A (en) Dpp iv inhibitor formulations
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
ECSP088429A (es) Diarilureas para el tratamiento de la hipertensión pulmonar
CR11299A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
CL2007003874A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
BRPI0922301A2 (pt) combinações de inibidor de hsp90
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CR10680A (es) Composiciones de inhibidores de chk1
NO20084712L (no) Nye farmasoytiske forbindelser
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
BRPI0510142A (pt) compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
UY30281A1 (es) Compuestos heterociclicos del tipo piridinas y piridazinas sustituidas, particularmente 4-(4-clorofenilamino)-7-(2-metilaminocarbonil-4-piridilmetoxi)furo-(2,3-d)piridazina, sales, polimorfos, solvatos o hidratos, composiciones y aplicaciones